Clinical trials of PD-L1/PD-1 antibodies in HCC show promising results; however, the response rate (20%) is lower than immunogenic tumors like melanoma and Hodgkin lymphoma (40%-90%). The gene discussed is PDCD1; the disease is melanoma.